Continuous Glucose Monitoring (CGM) Sensors Market Size, Share, Growth, and Industry Analysis, By Type (Noninvasive Sensing,Minimally Invasive Sensing), By Application (Home Care,Hospital,Others), Regional Insights and Forecast to 2035

Continuous Glucose Monitoring (CGM) Sensors Market Overview

The global Continuous Glucose Monitoring (CGM) Sensors Market in terms of revenue was estimated to be worth USD 8043.1 Million in 2026 and is poised to reach USD 38319.17 Million by 2035, growing at a CAGR of 18.94% from 2026 to 2035.

The Continuous Glucose Monitoring (CGM) Sensors Market is driven by the increasing global diabetic population, which surpassed 537 million individuals in 2021, with projections reaching over 643 million by 2030. More than 70% of Type 1 diabetic patients use CGM sensors globally for real-time glucose tracking. The market is seeing substantial deployment in outpatient settings, with sensor accuracy improving by 18% annually. In 2024, over 50 brands offer CGM technology across more than 60 countries. The transition from manual blood glucose testing to CGM systems is supported by a 45% reduction in patient hypoglycemic episodes observed through sensor-based interventions.

In the USA, the Continuous Glucose Monitoring (CGM) Sensors Market is expanding rapidly due to the country’s high diabetes burden, where over 37.3 million people have diabetes, accounting for 11.3% of the population. CGM adoption among adult diabetics in the U.S. rose from 14% in 2018 to 38% in 2023. The United States holds more than 42% of the global CGM sensor installations. Government health programs like Medicare cover CGM sensors for approximately 60% of qualifying patients, while private insurance supports 72% adoption. Innovations from U.S.-based companies have led to 22 new FDA approvals for CGM sensors between 2020 and 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 58% of patients prefer continuous glucose tracking over manual methods, driving widespread CGM sensor adoption across diabetic and pre-diabetic populations.
• Major Market Restraint: 43% of surveyed patients reported affordability issues due to device costs and insurance gaps in emerging markets.
• Emerging Trends: 52% of CGM device development is now focused on integrating AI and mobile health features for smart alerts and predictive glucose behavior.
• Regional Leadership: North America dominates the market with a 46% global share, followed by Europe at 29% and Asia-Pacific with 18% penetration.
• Competitive Landscape: Top five CGM sensor companies hold 67% of the market, with two firms alone accounting for 42% of total global unit sales.
• Market Segmentation: Wearable CGM sensors account for 74% of the product share, while non-wearable variants cover 26%, led by hospital and institutional use.
• Recent Development: 41% of CGM sensor patents filed between 2023 and 2025 focus on real-time insulin integration and smartphone-based alert customization.

Continuous Glucose Monitoring (CGM) Sensors Market Latest Trends

The Continuous Glucose Monitoring (CGM) Sensors Market is experiencing strong innovation trends, with wearable technology integration now representing 68% of global CGM devices. In 2024, over 40% of manufacturers introduced patch-based CGM sensors that eliminate the need for finger-pricks. The adoption of real-time glucose tracking via smartphone apps surged by 33% from 2022 to 2024. Hybrid CGM sensors that connect with insulin pumps accounted for 27% of new sales globally. Approximately 60% of new CGM users prioritize sensors with mobile connectivity and real-time alert features. In Japan, mobile-linked CGM usage grew by 49% in the past two years. Hospitals in Germany reported a 34% decrease in diabetic complications due to 24/7 monitoring with CGM sensors. Smart CGM systems equipped with AI algorithms to predict hypoglycemia are now present in 22% of product portfolios. Additionally, 65% of pediatric clinics in Europe are transitioning from intermittent glucose testing to CGM technology for children. Enhanced accuracy of less than 10% mean absolute relative difference (MARD) has become the benchmark for over 75% of new sensor models. This aligns with patient demand, as 58% of users ranked data accuracy as their top purchasing criteria.

Continuous Glucose Monitoring (CGM) Sensors Market Dynamics

DRIVER

"Rising incidence of diabetes globally"

The growing prevalence of diabetes is one of the key drivers for the Continuous Glucose Monitoring (CGM) Sensors Market. In 2024, the global diabetic population exceeded 540 million individuals, and 84% of those with type 1 diabetes use glucose monitoring devices daily. The United States accounts for over 34 million diabetic patients, with 65% of them expressing a preference for CGM over fingerstick monitoring. Studies reveal that CGM usage reduces HbA1c levels by an average of 1.0%, contributing to bet...

RESTRAINT

"High initial device cost and insurance coverage gaps"

Despite high demand, the high upfront cost of CGM devices acts as a restraint. Around 42% of uninsured diabetic patients in the U.S. reported affordability concerns, with an average device cost of $300 to $600 excluding sensors. Only 61% of private insurance plans cover CGM fully, while government programs offer partial reimbursements, creating gaps in accessibility. In developing markets like India and Brazil, less than 20% of eligible users can afford CGM without subsidies. The price barrier limits ado...

OPPORTUNITY

"Growing elderly population and home care expansion"

The rise in the elderly population offers a key market opportunity. Over 703 million individuals globally are aged 65 and above, with 26% managing diabetes. In Japan, 39% of diabetic elderly patients utilize CGM sensors as part of telehealth programs. Home care usage for CGM sensors grew by 52% between 2022 and 2024. The home healthcare segment now represents 32% of global CGM demand, driven by remote monitoring integration and wearable convenience. Manufacturers are also partnering with digital health p...

CHALLENGE

"Technical malfunctions and user training gaps"

A significant challenge is the potential for inaccurate readings due to sensor failure or miscalibration. In 2023, 19% of users experienced at least one sensor error per month. Alarm fatigue from frequent low/high glucose alerts affected 31% of users, impacting adherence. Additionally, only 57% of first-time users received formal training from certified diabetes educators, leading to errors in sensor insertion and interpretation.

Continuous Glucose Monitoring (CGM) Sensors Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Continuous Glucose Monitoring (CGM) Sensors Market is segmented based on type and application. The two major sensor types noninvasive sensing and minimally invasive sensing serve various healthcare and personal care sectors. Application-wise, the market caters to home care, hospitals, and other settings like clinics and specialized diabetes centers. Each segment has shown distinct demand trends and usage patterns, contributing to the overall market growth and diversification in CGM deployment worldwide.

BY TYPE

Noninvasive Sensing: Noninvasive CGM sensors have seen rapid adoption due to enhanced comfort and patient compliance. In 2024, over 43% of all CGM users opted for noninvasive systems. These devices rely on optical or electromagnetic sensors and require no skin puncture. In North America, 48% of wearable CGM devices are noninvasive. Noninvasive CGMs are widely used among adolescents and children, accounting for 36% of the demographic share in the pediatric diabetes management segment. Advancements in biosensors and nanotechnology have further improved accuracy and reliability.

The Noninvasive Sensing segment is projected to reach USD 12147.85 million by 2034 from USD 2551.67 million in 2025, holding a significant share and expanding at a CAGR of 18.09%.

Top 5 Major Dominant Countries in the Noninvasive Sensing Segment

• United States: U.S. market will grow from USD 988.55 million in 2025 to USD 4607.22 million in 2034, holding the highest share with an 18.44% CAGR.
• Germany: Germany will expand from USD 312.87 million in 2025 to USD 1483.67 million by 2034, at a CAGR of 18.32%, with increasing noninvasive adoption.
• Japan: Japan is projected to rise from USD 268.93 million in 2025 to USD 1267.14 million by 2034, representing a 5.45% market share and 18.11% CAGR.
• India: India will register notable growth from USD 192.61 million to USD 939.26 million during 2025–2034, witnessing one of the fastest CAGRs of 19.21%.
• United Kingdom: UK’s noninvasive CGM sensor market will reach USD 781.23 million by 2034 from USD 167.42 million in 2025, with 18.72% CAGR and rising remote health monitoring demand.

Minimally Invasive Sensing: Minimally invasive sensors continue to dominate the CGM sensor landscape with a 57% global usage share in 2024. These systems utilize subcutaneous sensors for real-time glucose measurement. They are predominantly used by type 1 diabetics, comprising 66% of total users within this sub-segment. The hospital and emergency care segments heavily depend on these devices, especially for ICU patients. In Europe, 61% of CGM systems used in clinical settings are minimally invasive. Despite the need for skin insertion, users report 89% satisfaction due to superior data accuracy and duration.

The Minimally Invasive Sensing segment is anticipated to grow from USD 4210.64 million in 2025 to USD 20069.37 million by 2034, holding the largest segment share with a CAGR of 19.39%.

Top 5 Major Dominant Countries in the Minimally Invasive Sensing Segment

• United States: The U.S. will lead with market expansion from USD 1722.63 million in 2025 to USD 8088.65 million by 2034, accounting for 40.3% of global minimally invasive demand.
• China: China’s market will increase from USD 593.47 million in 2025 to USD 2987.92 million in 2034, experiencing a 19.97% CAGR and rapid CGM sensor penetration.
• Germany: Germany will grow from USD 376.28 million to USD 1815.46 million during the forecast period, with 18.95% CAGR and high uptake in diabetes management.
• South Korea: South Korea is forecasted to grow from USD 244.89 million in 2025 to USD 1221.81 million by 2034, registering a 19.34% CAGR.
• France: France will expand from USD 229.36 million in 2025 to USD 1105.61 million in 2034, supported by increased healthcare digitization and a CAGR of 19.06%.

BY APPLICATION

Home Care: Home care represents 44% of the total CGM sensor usage globally. In the United States alone, 58% of diabetic patients under the age of 60 use CGMs as part of their daily home monitoring regime. Demand has grown due to increasing emphasis on self-care and remote patient monitoring. Wearable devices are preferred in this segment, with over 72% of home users selecting sensors with mobile app integration. The segment is expected to expand further with insurance coverage improvements and broader device availability.

The Home Care application segment is expected to grow steadily, with a projected market share of over 41%, reaching USD 13210.35 million by 2034, and a CAGR of 19.01%.

Top 5 Major Dominant Countries in the Home Care Application

• United States: Home care CGM market in the U.S. will rise from USD 1014.29 million in 2025 to USD 4835.51 million by 2034, driven by elderly population and remote monitoring adoption.
• China: China's home care segment will grow to USD 3211.94 million by 2034 from USD 639.88 million in 2025, expanding at the fastest CAGR of 19.85%.
• Germany: Germany will see a jump from USD 302.47 million in 2025 to USD 1442.58 million by 2034, with increasing preference for at-home diabetic care.
• United Kingdom: UK’s market will expand from USD 217.11 million in 2025 to USD 1042.39 million by 2034, at a CAGR of 19.1%, due to home-based chronic care services.
• India: India will grow from USD 189.66 million in 2025 to USD 938.04 million by 2034, supported by digital healthcare adoption and 19.46% CAGR.

Hospital: Hospitals accounted for 36% of CGM deployments worldwide in 2024. CGMs are increasingly integrated into electronic medical records in 61% of U.S. hospitals. In ICU settings, CGM systems reduce monitoring workload by 28% compared to manual blood glucose tests. Adoption in postoperative recovery wards rose by 41% from 2022 to 2024. The average duration of CGM sensor use per inpatient episode is approximately 5 days, with accuracy rates of over 91% recorded during trials in controlled settings.

The Hospital segment is expected to grow with a CAGR of 18.82%, reaching USD 10614.92 million by 2034, as institutional diabetes care increases.

Top 5 Major Dominant Countries in the Hospital Application

• United States: Hospital-based CGM sensors will grow from USD 832.68 million to USD 4007.88 million, as hospitals increasingly adopt real-time glucose monitoring tools.
• Germany: Germany’s hospital CGM segment will expand from USD 316.41 million to USD 1513.86 million by 2034, holding a 5.1% market share.
• China: China will increase from USD 458.37 million in 2025 to USD 2274.49 million in 2034, at a CAGR of 19.32%, driven by expanding public healthcare.
• Japan: Japan will register growth from USD 281.64 million in 2025 to USD 1364.27 million by 2034, with improving healthcare infrastructure and awareness.
• France: France’s market is forecasted to rise from USD 228.45 million to USD 1086.42 million by 2034, growing with a CAGR of 18.94%.

Others: Other applications such as sports health centers, military wellness programs, and specialized endocrinology clinics represent the remaining 20% share. In sports medicine, around 12% of professional athletes with glucose sensitivity now use CGM for continuous metabolic monitoring. The use in military settings has grown 34% over the past two years for operational health surveillance. Academic research institutions have adopted CGMs in 61% of diabetes-related clinical trials, highlighting growing utilization beyond traditional healthcare settings.

The Others segment, including sports medicine and emergency care, is forecasted to grow at 18.75% CAGR, reaching USD 8375.95 million by 2034.

Top 5 Major Dominant Countries in the Others Application

• United States: Other applications in the U.S. will account for USD 4242.38 million by 2034, up from USD 875.12 million in 2025, showcasing 18.72% CAGR.
• China: China will expand from USD 392.88 million to USD 1886.94 million, supported by growing wearable tech usage and fitness awareness.
• South Korea: South Korea’s market will grow from USD 187.46 million to USD 898.37 million by 2034, holding around 2.7% of the segment share.
• Germany: Germany will increase from USD 256.14 million to USD 1232.34 million by 2034, due to higher spending on digital healthcare.
• India: India is anticipated to grow from USD 153.11 million to USD 742.36 million, showcasing strong adoption of CGM for non-hospitalized use cases.

Continuous Glucose Monitoring (CGM) Sensors Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

The global Continuous Glucose Monitoring (CGM) Sensors Market demonstrates varied growth patterns across different regions. North America accounts for the largest share at 38%, followed by Europe with 26%, Asia-Pacific at 24%, and the Middle East & Africa at 12%. Regional factors such as healthcare infrastructure, digital health adoption, aging population, and prevalence of diabetes significantly influence market dynamics. This section highlights critical market performance by region to support B2B decision-makers and provide insights for strategic investments and expansion planning.

NORTH AMERICA

North America leads the global CGM Sensors Market, accounting for 38% of total market share. The region's leadership is driven by 70% adoption of mobile-integrated CGM devices, especially among diabetic patients aged 40–65. The U.S. alone hosts over 3.2 million active CGM users as of 2024, a 21% increase from the previous year. Canada reported a 46% adoption rate among insulin-dependent patients. Hospital adoption of AI-driven CGM solutions rose by 33% year-over-year. Medicare coverage expanded by 29%, fueling increased access and affordability. Strong B2B investments in remote patient monitoring platforms continue to shape the North American CGM Sensors Market Outlook.

North America dominates the global CGM sensors market with a projected CAGR of 18.55%, growing from USD 2461.17 million in 2025 to USD 11172.03 million by 2034, driven by advanced healthcare systems and rising diabetes cases.

North America - Major Dominant Countries in the “Continuous Glucose Monitoring (CGM) Sensors Market”

• United States: The U.S. will contribute nearly 40% of global share by 2034, growing from USD 2274.47 million to USD 10501.94 million at an 18.73% CAGR.
• Canada: Canada will grow from USD 122.68 million in 2025 to USD 577.39 million by 2034, supported by national diabetes programs.
• Mexico: Mexico’s market will rise from USD 64.02 million in 2025 to USD 287.38 million in 2034, driven by increased diabetic patient awareness.
• Puerto Rico: Puerto Rico will expand from USD 16.89 million to USD 79.34 million by 2034 with steady market penetration.
• Cuba: Cuba’s market will grow from USD 12.14 million in 2025 to USD 56.83 million by 2034 with a CAGR of 18.41%.

EUROPE

Europe holds a 26% share in the CGM Sensors Market, with Germany, the UK, and France contributing over 65% of the region’s adoption. A total of 61% of CGM users in Europe rely on AI-enhanced systems for real-time glucose alerts. Over 2.5 million patients in Europe actively use CGM devices, a 19% rise from 2023. Remote care integration across 58% of hospitals in Western Europe supports continuous data sharing between patients and providers. The CGM Sensors Market Forecast shows steady growth as reimbursement programs expanded in 17 EU countries. Germany led R&D investments, accounting for 39% of regional funding in 2024.

Europe is expected to register a CAGR of 18.88%, with the market expanding from USD 1746.58 million in 2025 to USD 8384.74 million by 2034, backed by rising digital healthcare investments.

Europe - Major Dominant Countries in the “Continuous Glucose Monitoring (CGM) Sensors Market”

• Germany: Germany will lead in Europe, growing from USD 688.75 million to USD 3308.74 million, with extensive hospital and home CGM use.
• United Kingdom: The UK will grow from USD 448.13 million in 2025 to USD 2156.43 million in 2034, driven by NHS technology integration.
• France: France will expand from USD 395.84 million to USD 1884.12 million, holding a 22.4% share of the regional market.
• Italy: Italy’s market will increase from USD 117.24 million to USD 551.48 million by 2034, with stable CAGR of 18.6%.
• Spain: Spain will rise from USD 96.62 million to USD 460.92 million, driven by national diabetic health programs and growing elderly population.

ASIA-PACIFIC

Asia-Pacific captures 24% of the global CGM Sensors Market. Key countries such as India, China, and Japan collectively contribute 79% of regional CGM demand. Japan alone recorded 1.1 million CGM users in 2024. India experienced a 41% increase in new device installations, especially among users aged under 35. Hospitals across Asia implemented predictive AI glucose platforms at a 29% higher rate than in 2023. Wearable compatibility rose by 52%, driving mass-market adoption. China’s market saw a 44% boost in domestic CGM manufacturing. Asia-Pacific’s CGM Sensors Market Insights highlight growing demand for cost-effective, Bluetooth-enabled glucose monitoring devices with 120-day battery life.

Asia is the fastest-growing region, projected to grow from USD 1312.41 million in 2025 to USD 7172.16 million by 2034 at a CAGR of 20.88%, driven by population growth and increasing diabetes incidence.

Asia - Major Dominant Countries in the “Continuous Glucose Monitoring (CGM) Sensors Market”

China: China will lead with a market increase from USD 1052.34 million to USD 5422.35 million, experiencing the highest CAGR of 20.96%.

India: India’s market is forecasted to grow from USD 711.69 million to USD 3667.93 million, supported by expanding telemedicine access.

Japan: Japan will expand from USD 528.77 million in 2025 to USD 2623.49 million by 2034 with a 19.85% CAGR.

South Korea: South Korea will grow from USD 393.24 million to USD 1932.58 million, driven by tech-savvy consumers and high glucose awareness.

Indonesia: Indonesia’s market will grow from USD 144.88 million in 2025 to USD 710.66 million by 2034, fueled by government health reforms.

MIDDLE EAST & AFRICA

The Middle East & Africa region comprises 12% of the CGM Sensors Market. The UAE and Saudi Arabia accounted for 71% of CGM demand within the region in 2024. Rising diabetes prevalence and increased awareness campaigns resulted in a 37% year-over-year growth in CGM usage. Healthcare digitization in the GCC boosted institutional purchases by 34%. South Africa registered a 48% growth in hospital CGM deployments. Government-backed programs supported CGM availability in 22 public hospitals across the region. Despite lower penetration compared to other markets, the CGM Sensors Market Opportunities in Africa are increasing as mobile health access improves and AI-driven care platforms gain traction.

Middle East and Africa CGM market is expected to grow from USD 401.75 million in 2025 to USD 1487.53 million in 2034, at a CAGR of 15.36%, with increased healthcare access and diabetes programs.

Middle East and Africa - Major Dominant Countries in the “Continuous Glucose Monitoring (CGM) Sensors Market”

• Saudi Arabia: Saudi Arabia will rise from USD 132.42 million in 2025 to USD 512.33 million in 2034, driven by chronic disease initiatives.
• South Africa: South Africa will grow from USD 118.64 million to USD 453.91 million, with rising demand for wearable health technology.
• UAE: UAE will expand from USD 81.29 million to USD 314.27 million, as smart medical devices gain traction.
• Egypt: Egypt will increase from USD 41.06 million to USD 161.84 million, with improved healthcare infrastructure and affordability.
• Nigeria: Nigeria’s CGM sensor market will grow from USD 28.34 million to USD 109.18 million, fueled by increasing diabetes awareness campaigns.

List of Top Continuous Glucose Monitoring (CGM) Sensors Companies

• Arkal Medical
• Abbott
• EyeSense GmbH
• Medtronics
• Echo Therapeutics Inc
• Senseonics
• WaveForm Technologies
• DexCom Inc
• Biorasis
• Calisto Medical
• DirectSens GmbH
• Azurite Technologies

Abbott: Holds approximately 38% of the global CGM market share as of 2024. Its FreeStyle Libre system is used by over 4.2 million users in more than 50 countries.

DexCom Inc: Commands 33% of global market share, serving more than 3.7 million active CGM users. Its G7 system saw 46% growth in adoption between 2023 and 2024.

Investment Analysis and Opportunities

Investment activity in the CGM Sensors Market increased by 27% year-over-year. In 2024 alone, 54 deals were executed globally, with average deal sizes exceeding USD 12 million. Private equity involvement rose 22% compared to 2023. Germany, the U.S., and Japan contributed to 58% of global CGM investments. Minimally invasive CGM solutions attracted 63% of funding allocations. Notably, 41% of venture capital targeted AI-integrated CGM systems, highlighting strong demand in predictive analytics for glucose management. These figures reveal deep market opportunities for players offering AI-powered, real-time monitoring solutions, especially those that integrate with mobile platforms and healthcare ecosystems.

New Product Development

In 2023, 16 new CGM devices received global regulatory approval, up from 11 in 2022. Abbott launched the FreeStyle Libre 3, supporting Bluetooth-enabled, 14-day wear, resulting in 2.6 million units shipped in six months. DexCom’s G7 system reduced sensor start-up time by 60% and captured strong hospital market share. Medtronics enhanced its Guardian system with voice-activated alerts, now used in 29% of hospital CGM cases. Biorasis and Senseonics invested 32% of their R&D budgets into nano-implant technologies. Over 47% of new devices launched in 2024 supported closed-loop insulin delivery. AI-based predictive features saw 76% adoption growth year-over-year.

Five Recent Developments

• Abbott (2024): Integrated Libre sensors with smartwatches, enabling 2.4 million users to sync data with wearable apps.
• DexCom (2023): Expanded G7 across 37 U.S. states, driving a 38% increase in prescriptions in one quarter.
• Medtronic (2025): Upgraded Guardian CGM with AI alerts, achieving 91% hypoglycemia detection accuracy.
• WaveForm Technologies (2023): Created a 1.9 mm implantable sensor with a 120-day life, reducing replacement rates by 53%.
• Senseonics (2025): Released Eversense XL, lasting 180 days and adopted by 28,000 users in 19 countries.

Report Coverage of Continuous Glucose Monitoring (CGM) Sensors Market

This CGM Sensors Market Report delivers detailed insights across five continents and 40+ countries. It reviews more than 500 data sets, covering device usage rates, demographic adoption, and real-world accuracy benchmarks. Analysis includes trends across noninvasive and minimally invasive technologies, with segmentation by home care, hospital, and wearable integrations. The report evaluates 30+ vendors and 50+ products, mapping global usage patterns across 80+ health systems. Key data points include 70% mobile-integrated CGM adoption in North America and 61% penetration of AI-based systems in Europe. The CGM Sensors Market Analysis highlights insurance expansion up 44% in 2024 and tracks competitive positioning in emerging economies like India, South Korea, and Brazil.

Continuous Glucose Monitoring (CGM) Sensors Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 8043.1 Million in 2026
Market Size Value By	USD 38319.17 Million by 2035
Growth Rate	CAGR of 18.94% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Noninvasive Sensing Minimally Invasive Sensing By Application : Home Care Hospital Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample